Fundamental Data for MRK

MERCK & CO(NYSE:MRK)

Merck & Co., Inc. is a global research-driven pharmaceutical company that discovers, develops, manufactures and markets a broad range of human and animal health products, directly and through its joint ventures, and provides pharmaceutical benefit services through Merck-Medco Managed Care, L.L.C. Its operations are principally managed on a products and services basis and are comprised of two reportable segments: Merck Pharmaceutical and Merck-Medco.

# Employees: 55200

Address: One Merck Drive P.O. Box 100,Whitehouse Station,NJ,USA

Phone: 908 423-1000

Fax: 908 735-1253

Website: www.merck.com

Email:

Sector: Medical

Industry: MED-DRUGS

Executive Officers

Richard T. Clark (Chmn.; Presi.; C.E.O.; Princ. Exec. Off.; Dir.)

Peter N. Kellogg (Exec. V.P.; C.F.O.; Princ. Fin. Off.l)

John Canan (Sr. V.P.; Princ. Acctg. Off.; Contro.)

Steven F. Goldstone (Dir.)

Thomas H. Glocer (Dir.,)

Dividend

Ex-Dividend Date: 9/2/2009

Annual Dividend: $1.52

Current Dividend Yield: $4.17

Dividend Paid (3 months): $0.38

Indicated Dividend: $0.46

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/9/2010

Mean EPS (Next Qtr): $0.79

Mean EPS (Year): $3.28

Mean Estimate(Long Term): $3.25

P/E Ratio(Based on EPS estimate): 11.120

Number of Estimates: 17

Shares Performance

Period	MRK	Compare to S&P
YTD	19.93 %	-0.74 %
4 Weeks	12.43 %	11.21 %
12 Weeks	12.81 %	6.35 %

Shares Information

Analyst Coverage: Y

Avg Volume: 26150740

Shares Outstanding: 2108M

Market Cap: $76.89B

52 Week High: $36.46

52 Week Low: $20.99

P/E Ratio: 10.920

PEG Ratio: 3.420

Split: On 2/17/1999 MRK split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: 8.43 %

EPS Growth in Last Year: 12.50 %

Sales Growth in Last Quarter: 2.54 %

Sales Growth in Last Quarter: 1.78 %

Financials

Qtr Book Value: $3.03

Cash Flow/Share: $8.59

Change in Payout Ratio: -0.080

Price/Sales: 3.290